# CKD-702 Plus Irinotecan in Gastric Cancer

> **NCT05750290** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** CKD-702 in combination with irinotecan

## Key facts

- **NCT ID:** NCT05750290
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05750290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05750290, "CKD-702 Plus Irinotecan in Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05750290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*